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Abstract
Background Sarcopenia, the progressive decline in skeletal muscle mass and function with age, is a debilitating condition. It
leads to inactivity, falls, and loss of independence. Despite this, its cause(s) and the underlying mechanism(s) are still poorly
understood.
Methods In this study, small skeletal muscle ﬁbre bundles isolated from the extensor digitorum longus (a fast-twitch muscle)
and the soleus (a slow-twitch muscle) of adult mice of different ages (range 100–900 days old) were used to investigate the
effects of ageing and dihydrotestosterone (DHT) treatment on protein synthesis as well as the expression and function of
two amino acid transporters; the sodium-coupled neutral amino acid transporter (SNAT) 2, and the sodium-independent L-
type amino-acid transporter (LAT) 2.
Results At all ages investigated, protein synthesis was always higher in the slow-twitch than in the fast-twitch muscle ﬁbres
and decreased with age in both ﬁbre types. However, the decline was greater in the fast-twitch than in the slow-twitch ﬁbres
and was accompanied by a reduction in the expression of SNAT2 and LAT2 at the protein level. Again, the decrease in the ex-
pression of the amino acid transporters was greater in the fast-twitch than in the slow-twitch ﬁbres. In contrast, ageing had no
effect on SNAT2 and LAT2 expressions at the mRNA level. Treating the muscle ﬁbre bundles with physiological concentrations
(~2 nM) of DHT for 1 h completely reversed the effects of ageing on protein synthesis and the expression of SNAT2 and LAT2
protein in both ﬁbre types.
Conclusion From the observations that ageing is accompanied by a reduction in protein synthesis and transporter expression
and that these effects are reversed by DHT treatment, we conclude that sarcopenia arises from an age-dependent reduction in
protein synthesis caused, in part, by the lack of or by the low bioavailability of the male sex steroid, DHT.
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Introduction
Sarcopenia, a skeletal muscle wasting as a result of old age,
is a debilitating condition that is characterized by the pro-
gressive and gradual (rate 1–5% per annum depending on
age) decline in skeletal muscle mass, strength, and func-
tion.1 It manifests itself predominantly in the elderly (E;
generally in people >80 years) and leads to inactivity, in-
creased susceptibility to falls, and eventually to loss of in-
dependence.2 Falls are a major health concern because
they lead to injury, pain, hospitalization, and increased
mortality. Despite its huge socioeconomic and health impli-
cations, the cause(s) and mechanism(s) underlying
sarcopenia are still poorly understood.
In young (Y) adult men, skeletal muscle forms ~40–50%
of body mass and acts as the main store of proteins.3
Therefore, in addition to its main physiological functions
of respiration, postural support, and the control of move-
ment, skeletal muscle is also important in the maintenance
of body shape, structure, and composition. Skeletal muscle
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mass is maintained by the ﬁne balance between protein
synthesis and breakdown. Therefore, a decrease in skeletal
muscle mass, such as that seen during ageing, must reﬂect
an imbalance between these two processes. Although sev-
eral studies have previously reported a 30–40% reduction
in mixed protein synthesis with age,4,5 the anabolic effects
of amino acids are still intact in the E.6 Together, these
ﬁndings suggest that sarcopenia may arise from a failure
in the transmembrane transport of amino acids into and
out of skeletal muscle ﬁbres.
Amino acids enter and leave cells through highly special-
ized proteins known as amino acid transporters that are lo-
cated on the plasma/cell membrane (=sarcolemma in
skeletal muscle) and that play an important role in protein
turnover.7 Although numerous amino acid transporters are
present in cells,8 only two, the sodium-coupled neutral
amino acid transporter (SNAT) 2 and the sodium-
independent L-type amino acid transporter (LAT) 2, have
been consistently found in skeletal muscle in signiﬁcant
quantities.9,10 Moreover, these transporters work together
to transport essential amino acids into muscle cells (=mus-
cle ﬁbres). Thus, SNAT2 transports small neutral amino
acids such as glutamine into muscle ﬁbres. These are then
exchanged by LAT2 for the branched chain, essential amino
acids required for protein synthesis.11,12 However, little is
known about the effects of ageing on the number and
function of these amino acid transporters in mammalian
skeletal muscle ﬁbres.
Sex steroids are important regulators of body shape,
structure and, composition. For example, treating adult fe-
male rats,13 hypogonadal men,14 and E men with low tes-
tosterone (T) concentrations15 with T or any of its many
derivatives for several weeks increases lean body mass
and decreases fat content, suggesting that sex steroids
are essential for the maintenance of skeletal mass and
may be important in the management of sarcopenia. Al-
though the concentration of free T in plasma decreases
with age in both men and women,16 and T supplementa-
tion has been shown to increase lean body mass, T is not
the most potent sex steroid in the body.17 Instead, in target
tissues such as the skin, prostate, and brain, it is irrevers-
ibly metabolized to dihydrotestosterone (DHT) by the en-
zyme 5α-reductase.18 Additionally, recent studies suggest
that DHT, but not T, may be the more potent anabolic–
androgenic steroid in mammalian skeletal muscle ﬁbres.19
However, it is unknown whether DHT can reverse/arrest
the development of sarcopenia.
The primary aims of this study were to investigate (i) the
effects of ageing and DHT treatment on protein synthesis in
mouse fast-twitch and slow-twitch skeletal muscle ﬁbre
bundles and (ii) the effects of ageing and DHT treatment
on the expression and function of SNAT 2 and LAT 2 in in-
tact mouse fast-twitch and slow-twitch skeletal muscle ﬁbre
bundles.
Methods
Small skeletal muscle ﬁbre bundles
All the experiments reported here were performed at room
temperature (~20°C) using small skeletal muscle ﬁbre bun-
dles isolated from the extensor digitorium longus (EDL, a
fast-twitch muscle that is composed mostly of type 2 ﬁ-
bres) and the soleus (a slow-twitch muscle that is com-
posed predominantly of type 1 ﬁbres) muscles of Y
(~100 days old), middle-aged (M; ~350 days old) and E
(>700 days old) female C57BL/6 mice killed by cervical dis-
articulation as recommended by UK legislation. Additionally,
all the experiments conformed to the University of East An-
glia Animal Welfare and Ethical Review Board guidelines.
During the experiments, the muscles and muscle ﬁbre bun-
dles were bathed in mammalian Ringer’s solution continu-
ously bubbled with 95% O2 and 5% CO2 (for details of
the Ringer’s solution refer to20).
Reverse transcription polymerase chain reaction
Total RNA was extracted from the EDL and soleus muscles of
Y (n = 6), M (n = 6), and E (n = 6) mice using TRIzol® reagent fol-
lowing the manufacturer’s instructions (Life Technologies,
Paisley, UK). Brieﬂy, the muscles isolated from each animal
were weighed, snap frozen in liquid nitrogen, pulverized,
and mixed with 100μL ice-cold TRIzol. The mixture was cen-
trifuged at 4°C, and the supernatant was mixed with chloro-
form. The aqueous phase was separated, mixed with
isopropanol, and left to incubate at room temperature for
10min. It was centrifuged, and the precipitated RNA was
cleaned using an RNeasy Mini Kit (Qiagen, Manchester, UK)
and redissolved in RNAse-free water. The quality and quantity
of the RNA extracted were determined spectrophotometri-
cally, and 1μg was reverse transcribed using QuantiTect Re-
verse Transcription Kit (Qiagen, Manchester, UK) following
the manufacturer’s instructions. Finally, the expression of
SNAT2, LAT2, and α-actin in the samples was determined af-
ter 35 cycles of ampliﬁcation at 55°C using the following
primers:
SNAT2:
Forward: 5′ ATCGTGGTGATTTGCAAGAA 3′
Reverse: 5′ GTCTGCGGTGCTATTGAATG 3′
LAT2
Forward: 5′ GCCCTCACCTTCTCCAACTA 3′
Reverse: 5′ CCATGTGAGGAGCAACAAAC 3′
α-Actin
Forward: 5′ GCCCATCTATGAGGGCTATG 3′
Reverse: 5′ AATCTCACGTTCAGCTGTGG 3′
All the experiments were performed using muscles from
three mice, and each experiment was repeated at least twice.
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Effects of ageing on the expression of SNAT2 and
LAT2
To determine the effects of ageing on the expression of
SNAT2 and LAT2, small muscle ﬁbre bundles isolated from
the EDL and the soleus muscle of Y (n = 4), M (n = 4), and E
(n = 4) female mice were used. Within 2min of isolation, the
bundles were snap frozen in liquid nitrogen and pulverized.
Cytosolic and membrane proteins were extracted using
NP40 lysis buffer as previously described in.21 Finally, the pro-
teins were immunoblotted for the expression of SNAT2 and
LAT2 as described in the succeeding texts.
Effects of dihydrotestosterone treatment on the
expression of SNAT2 and LAT2
In another experiment, the effects of treating ﬁbre bundles
isolated from mice of different ages with physiological con-
centrations (~2 nM) of DHT22 were investigated. The bundles
were divided into two equal groups. Group 1 (controls; n = 18
ﬁbre bundles) was treated with the Ringer’s solution contain-
ing 107.6μM ethanol (the vehicle used to dissolve the DHT)
for 1 h. Group 2 (experiment; n = 18 ﬁbre bundles) was
treated for the same duration with Ringer’s solution contain-
ing 630 pgml1 (2.17 nM) DHT (5α-Androstan-17β-ol-3-one;
Sigma, Gillingham, Dorset, UK). At the end of the treatments,
the bundles were snap frozen in liquid nitrogen, pulverized,
and proteins were extracted as described in.21 Finally, the
proteins were immunoblotted for the expression of SNAT2
and LAT2 as described in the succeeding texts.
Effects of ageing and DHT treatment on protein
synthesis
The effects of ageing and DHT treatment on protein synthesis
were determined as previously described in.12 Brieﬂy, fast-
twitch and slow-twitch muscle ﬁbre bundles isolated from Y
and E mice were divided into two equal groups. Half (con-
trols; n = 12 ﬁbre bundles) was treated for 1 h with the stan-
dard Ringer’s solution containing 107.6μM ethanol plus
2mM C14-labelled isoleucine [L-(U-14 C) Ile; radioactivity level
3.46μCiml1] (purchased from PerkinElmer, Buckingham-
shire, UK). The other half (treatment/experimental group;
n = 12 ﬁbre bundles) was treated with the Ringer’s solution
containing 2.17 nM DHT plus L-[U-14 C] Ile for 1 h. At the
end of the experiment, the ﬁbre bundles were washed with
ice-cold phosphate buffered saline and the excess phosphate
buffered saline was blotted. The bundles were snap frozen in
liquid nitrogen, pulverized, and mixed with NP40 buffer. The
proteins were precipitated using trichloroacetic acid, washed
three times with ice cold acetone, and redissolved in 200μL
of KOH. The amount of proteins in each lysate was
determined using the quick Bradford assay, and the remain-
ing lysate was mixed with an equal amount of Ecoscint A liq-
uid scintillant (Fisher Scientiﬁc, Leicestershire, UK). The
radioactivity of the mixture was determined 1 h and 24 h af-
ter the end of each experiment using a HIDEX 300SL liquid
scintillation counter (Lablogic Systems Ltd, Shefﬁeld, UK). Ad-
ditionally, each experiment was repeated at least twice.
Immunoblotting
To determine the effects of ageing and DHT treatment on the
expression of SNAT2 and LAT2 proteins in the two muscle ﬁ-
bre types, equal amounts of the proteins collected from the
experiments described in the preceding texts were
immunoblotted as previously described in.12,21 Brieﬂy, 10μg
of the proteins was separated by standard gel electrophoresis
and transferred onto nitrocellulose membranes. The mem-
branes were blocked for non-speciﬁc antibody binding using
5% milk. They were then immunoblotted for the expression
of SNAT2 (sc-166366; Santa Cruz Biotechnology, Santa Cruz,
Ca, USA) and LAT2 (ab123893) from Abcam (Abcam, Cam-
bridge, UK). The peEF2 antibody was a gift from Prof. Chris
Proud, University of Southampton. Finally, they were visual-
ized using SuperSignal WestPico chemiluminescence sub-
strate (Perbio Science UK Ltd, Cramlington and
Northumberland, UK) and exposure to ﬁlm.
To check for loading, the membranes were stripped and
reprobed with a pan-actin antibody (ab3280, Abcam, Cam-
bridge, UK). All the blots were run in duplicate, and each ex-
periment was repeated at least twice.
To determine the expression of SNAT2 and LAT2 in the var-
ious muscle ﬁbre bundles, the blots were digitized, and the
intensity of the various mRNA and protein bands were
analysed using Scion Image® from NIH and normalized to that
of the loading control (actin).
Statistical analysis
Statistical analysis of the data was performed using SPSS sta-
tistical program (IBM, UK). The data obtained from each ﬁbre
type under control and after the various treatments were
compared using a one-way ANOVA with Bonferroni post hoc
test and a P< 0.05 was considered statistically signiﬁcant.
Results
Effects of ageing on skeletal muscle mass
Figure 1 shows some of the basic observations from this
study. As the results show, ageing led to a marked decline
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in the weight of both the EDL and soleus muscles (Figure 1A
and B). For example, the EDL and soleus muscles from 100-
day-old mice weighed 31.9 ± 2.2mg and 33.5 ± 2.4mg, re-
spectively. However, by the time the mice were ~730 days
old, the weight of the muscles had declined to 18.3 ± 2.1mg
and 26.3 ± 1.6mg, respectively (Figure 1A). The effects be-
came more apparent when the muscle weights were normal-
ized to body mass (Figure 1B). Presented this way, the weight
of the EDL decreased from ~1.4% body weight in the 100-day-
old mice to 0.4% body weight in the 730-day-old mice (
Figure 1B).
Effects of ageing on protein synthesis
As the results displayed in Figure 1C show, at all ages investi-
gated, protein synthesis was always higher in the slow-twitch
than in the corresponding fast-twitch muscle ﬁbres. Also, the
difference in protein synthesis between the two ﬁbre types
increased with age. Thus, protein synthesis in the slow-twitch
ﬁbres isolated from 100-day-old mice was ~49% higher than
that of the fast-twitch ﬁbres from the same mice. However,
by the time the mice were 730 days old, this difference had
risen to ~75% (Figure 1C).
As the results also show, ageing led to a marked decrease
in protein synthesis in both ﬁbre types (Figure 1C). However,
the effects were greater in the fast-twitch ﬁbres than in the
slow-twitch ﬁbres. Thus, ageing led to a 42 ± 3.4% decline in
protein synthesis in the fast-twitch ﬁbres but only to a 33
± 2.7% decrease in the slow-twitch ﬁbres (Figure 1C).
The phosphorylation of eukaryotic elongation factor (eEF)
2 in fast-twitch and slow-twitch ﬁbres is shown in Figure 1
D. As the results show, the phosphorylation of eEF2 was al-
ways higher in the fast-twitch than in the slow-twitch muscle
ﬁbres (Figure 1D).
Effects of ageing on the expression of SNAT2 and
LAT2
As mentioned in the ‘Introduction’ section, SNAT2 and LAT2
work together to transport the branched chain, essential
Figure 1 Ageing decreases skeletal muscle mass and protein synthesis. Bar graphs showing the effects of ageing on muscle weight (A and B) and pro-
tein synthesis (C) in the extensor digitorium longus (F; clear bars) and soleus (S; ﬁlled bars) of young (Y), middle-aged (M) and elderly (E) mice. (D) A
typical Western blot showing the phosphorylation of eEF2 in the extensor digitorium longus (F) and soleus (S) of mice ~100 days old. Note that ageing
decreases skeletal muscle mass and protein synthesis in both ﬁbre types. Additionally, the extensor digitorium longus expresses more phosphor-eEF2
than the soleus. The data in (A) and (B) are from whole muscles, whereas those in (C) and (D) are from small muscle ﬁbre bundles. *†P< 0.05 when
the data from the elderly and the middle-aged mice were compared with that from the young mice. € ± P< 0.05 when the data from the middle-aged
mice were compared with those from the elderly mice.
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amino acids that are required for protein synthesis into skel-
etal muscle ﬁbres. Therefore, in another experiment, we de-
termined whether the reduction in protein synthesis
reported in the preceding texts was a result of an age-
dependent decline in the number of amino acid transporters.
As the results displayed in Figure 2 show, ageing signiﬁcantly
decreased in the expression of SNAT2 and LAT2 proteins in
both muscle ﬁbre types. Moreover, the decrease in SNAT2
was greater than that of LAT2 in both ﬁbres types. It was also
higher in the fast-twitch ﬁbres (~35%) than in the slow-twitch
ﬁbres (~25%).
To determine the mechanism underlying this age-
dependent decline in SNAT2 protein expression and function,
we investigated the effects of ageing on SNAT2 and LAT2
mRNA. As the results displayed in Figure 3 show, ageing had
no effect on the mRNA for both transporters in the two mus-
cle ﬁbre types (Figure 3A and B), suggesting that lack of
mRNA was not the cause of the age-dependent decline in
SNAT2 and LAT2 expressions at the protein level.
Effects of DHT treatment on protein synthesis and
amino acid transporter expression
To determine whether the decrease in protein synthesis with
ageing was a result of low concentrations of DHT in muscles,
we investigated the effects of treating fast-twitch and slow-
twitch skeletal muscle ﬁbre bundles with physiological con-
centrations of DHT. As the results displayed in Figure 4A
show, treating the ﬁbre bundles isolated from Y mice with
DHT had no effect on protein synthesis in the slow-twitch
muscle ﬁbres. However, it led to a 17.8 ± 3% increase in pro-
tein synthesis in the fast-twitch ﬁbres.
In contrast, treating the ﬁbre bundles isolated from E mice
with DHT completely reversed the age-dependent decline in
protein synthesis. Thus, in the E mice, the DHT treatment
led to a 44 ± 5% and a 21 ± 3% increase in protein synthesis
in the fast-twitch and slow-twitch ﬁbre bundles, respectively (
Figure 4A).
DHT treatment also abolished the age-dependent decline
in SNAT2 (Figure 4B) and LAT2 (Figure 4C) protein in both
muscle ﬁbre types.
Discussion
Protein synthesis in fast- and slow-twitch ﬁbres
A key ﬁnding in the present study is the observation that, at all
ages investigated, protein synthesis was always higher in the
slow-twitch (type 1) than in the fast-twitch (type 2) ﬁbres,
and this difference became greater with age. Although type
1 ﬁbres isolated from the vastus lateralis of human subjects
have been shown to have higher fractional protein synthesis
rates than type 2a ﬁbres from the same muscle,23 this is the
ﬁrst study to show that the difference in the rate of protein
synthesis between the two ﬁbre types increases with age. In
previous studies, the difference was attributed to the levels
of phosphorylated eEF2 and adenosine monophosphate-
activated protein kinase present in the ﬁbre types.23 In mam-
malian skeletal muscles, the phosphorylation of these pro-
teins is higher in fast-twitch than in slow-twitch ﬁbres and is
associated with decreased protein synthesis. However, from
the current and previous12 ﬁndings, we do not think that the
phosphorylation of eEF2 and adenosine monophosphate-
activated protein kinase is the only cause of the ﬁbre type dif-
ferences in protein synthesis. Our results suggest that other
factors such as the levels of amino acid transporters expressed
by the various muscle ﬁbres may also play a role.
Figure 2 Ageing decreases the expression of sodium-coupled neutral amino acid transporter 2 and LAT2 proteins. Bar graphs and typical immunoblots
showing the effects of ageing on the expression of sodium-coupled neutral amino acid transporter 2 and L-type amino-acid transporter proteins in
small muscle ﬁbre bundles isolated from the extensor digitorium longus (F; clear bars) and soleus (S; ﬁlled bars) of young (Y), middle-aged (M), and
elderly (E) mice. Note that ageing decreases the expression of both proteins in the fast-twitch and slow-twitch ﬁbre bundles. *†P< 0.05 when the data
from the elderly and the middle-aged mice were compared with those from the young mice.
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Effects of ageing on protein synthesis in
mammalian skeletal muscle ﬁbres
Another important ﬁnding in the present study was the ob-
servation that protein synthesis in both ﬁbre types
decreased with age and that the decline was greater in
the fast-twitch ﬁbres than in the slow-twitch ﬁbres. Al-
though a number of previous studies have reported a re-
duction in the fractional synthetic rate of mixed muscle
and speciﬁc myoﬁbrillar proteins with age,3,24,25 these
Figure 3 Ageing has no effect on sodium-coupled neutral amino acid transporter 2 and L-type amino-acid transporter mRNA. Bar graphs and immuno-
blots showing the effects of ageing on the expression of sodium-coupled neutral amino acid transporter 2 and L-type amino-acid transporter mRNA in
small muscle ﬁbre bundles isolated from the extensor digitorium longus (F; clear bars) and soleus (S; ﬁlled bars) of young (Y), middle-aged (M), and el-
derly (E) mice. Note that ageing has no signiﬁcant effect on the mRNA for both proteins in the fast-twitch and slow-twitch ﬁbre bundles. L, liver samples.
Figure 4 Dihydrotestosterone treatment reverses the effects of age on protein synthesis and the expression of sodium-coupled neutral amino acid
transporter 2 and L-type amino-acid transporter proteins. Bar graphs and typical western blots showing the effects of treating small muscle ﬁbre bun-
dles isolated from the extensor digitorium longus (F; clear bars) and soleus (S; ﬁlled bars) of young (Y), middle-aged (M), and elderly (E) mice with
physiological concentrations of dihydrotestosterone for 1 h on protein synthesis (A), sodium-coupled neutral amino acid transporter 2 protein expres-
sion (B), and L-type amino-acid transporter protein expression (C). Note that treating the ﬁbre bundles with dihydrotestosterone reverses the age-de-
pendent decline in protein synthesis as well as the age-dependent decrease in sodium-coupled neutral amino acid transporter 2 and L-type amino-acid
transporter protein expression. *†P< 0.05 when the data from the elderly and the middle-aged mice were compared with those from the young mice.
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studies were performed on muscle biopsies from human
subjects. Moreover, most of the biopsies were from mus-
cles such as the quadriceps femoris and vastus lateralis that
consist of a mixture of fast-twitch and slow-twitch ﬁbres
and until recently, it was impossible to separate the frac-
tional synthesis rate of the various ﬁbre types.23 Therefore,
from these studies, it was impossible to attribute the age-
dependent decline in protein synthesis to a speciﬁc ﬁbre
type. Although ageing has also been shown to decrease
the fractional synthetic rates of type 2a and 2x myosin
heavy chains in human muscle biopsies,3,24 this is the ﬁrst
study to show that the effects of ageing on protein synthe-
sis are greater in fast-twitch than in slow-twitch ﬁbres, and
that this difference increases with age. Together, these
ﬁndings suggest that sarcopenia may arise, in part, from
an age-dependent decline in muscle protein synthesis.
Effects of ageing on amino acid transporter
expression in mammalian skeletal muscle ﬁbres
In the present study, the decrease in protein synthesis with
age was accompanied by a decline in both SNAT2 and LAT2
proteins. SNAT2 is a system A amino acid transporter that
belongs to the SLC38 gene family. It mediates the sodium-
coupled transport of small neutral amino acids such as glu-
tamine, alanine, etc. into muscle ﬁbres. These are then ex-
changed, by LAT2, for the large branched chain amino
acids such as leucine, histidine, etc. that are essential for
protein synthesis in skeletal muscle.12 Like the decrease in
protein synthesis with age, the decline in SNAT2 expression
was greater in the fast-twitch ﬁbres than in the slow-twitch
ﬁbres. Here, we speculate that the decrease in protein syn-
thesis and the expression of SNAT2 with age are linked and
that they are responsible for the development of
sarcopenia.
Previously, one of the reasons advanced to explain the
decline in protein synthesis with age was the reduction in
the mRNA required for protein translation.26 For example,
the age-dependent decline in type 2a and 2x myosin heavy
chains was associated with a large decrease in the mRNA
for these proteins.24 However, as the results reported here
show, ageing did not affect the SNAT2 and the LAT2 mRNA
levels in mouse skeletal muscle ﬁbres. Together, these ﬁnd-
ings suggest that the effects of age on mRNA expression
may vary from protein to protein, and that the changes in
the expression of SNAT2 and LAT2 may arise from post-
transcriptional control of mRNA translation. Indeed, a num-
ber of studies have previously reported changes in the ex-
pression of various microRNAs with age.27 However, the
role microRNAs play in the age-dependent decline in protein
synthesis and hence in the development of sarcopenia re-
mains uncertain.
Effects of DHT treatment on the age-dependent
decline in protein synthesis and amino-acid
transporter expression
A novel ﬁnding in the present study was the observation that
treating small skeletal muscle ﬁbre bundles isolated from E
mice with physiological concentrations of DHT rescues the
age-dependent decline in protein synthesis in both muscle ﬁ-
bre types. Moreover, the effects of DHT treatment, like those
of ageing on protein synthesis, were greater in the fast-twitch
than in the slow-twitch ﬁbres. DHT treatment was also ac-
companied by an increase in the expression of SNAT2 and
LAT2 in both ﬁbre types.
In humans, from the age of 50 years onwards, the plasma
levels of T decrease progressively with age, whereas ageing
has the opposite effect on the plasma concentration of ste-
roid hormone binding globulin whose concentration in-
creases.22,28 Both changes severely curtail the levels of free
plasma T and hence its bioavailability. Moreover, the age-
dependent decrease in plasma T concentrations parallels
the decline in skeletal muscle mass and function with age,
suggesting that the lack of or the reduced bioavailability of
T may be one of the causes of sarcopenia.
Although a number of studies have previously demonstrated
the beneﬁcial effects of T replacement therapy (TRT), recent stud-
ies suggest that DHT and not T may be the main anabolic hor-
mone in skeletal muscle.12,19 It has also been suggested that T
may exert its anabolic effects in skeletal muscle through the intra-
muscular release of an intermediary such as insulin-like growth
factor 1.29 Here, we speculate that this intermediary is DHT.
Asmentioned in the preceding texts, DHT treatment increases
the expression of both SNAT2 and LAT2 protein in E muscle ﬁ-
bres. Although the mechanism involved was not investigated in
the present study, the rapidity with which it occurred suggest
that it involves the recruitment of SNAT2 and LAT2 heavy chains
from an intracellular compartment. The expression of SNAT2 is
regulated by many factors including pH, amino acid deprivation,
and growth factors such as insulin and insulin-like growth factor
1. Moreover, like in the current study, these factors increase the
expression and function of SNAT2 within minutes.30 It is also
thought that these effects do not involve transcription and trans-
lation. Instead, it is thought that they stimulate the recruitment
of SNAT2 from an intracellular compartment in a similar manner
to that of insulin on GLUT4 activation.30 However, whether DHT
increases the expression of SNAT2 and LAT2 protein through a
similar mechanism is uncertain.
Use of DHT in the management of sarcopenia
As mentioned in the preceding texts, the free plasma concentra-
tion of T (i.e. bioavailable T) in men decreases with age, and the
decline corresponds well with the onset and progression of
sarcopenia.22,28 This ﬁnding has fuelled many trials in the use
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of TRT as a possible treatment for sarcopenia. However, in E
men,TRT reverses some but not all the effects of sarcopenia.17,22
It is also associated with several side effects including an in-
crease in the risk of developing prostate cancer and gynecomas-
tia, alterations in the composition of plasma lipids, and increased
cardiovascular events. Moreover, most of these adverse effects
are mostly a result of the aromatization of T to oestrogen by
the enzyme aromatase and its reduction to DHT by 5α-
reductase,17,31 suggesting that the use of a non-metabolizable
anabolic–androgenic steroid may be a safer option.
One such steroid is DHT. However, very few studies have
investigated the clinical use of DHT in the management of
sarcopenia. DHT has many advantages over T. Firstly, it is nei-
ther aromatized nor reduced in target tissues. Secondly, in
peripheral tissues, most of the DHT is thought to be produced
locally,22 suggesting that its use can be targeted at speciﬁc
tissues. Thirdly, treatment of E men with a transdermal DHT
gel has been shown to be effective in the management of
some of the effects of sarcopenia without the side effects
of T.32,33 Fourthly, the results we report here suggest that
DHT treatment may be able to reverse the effects of ageing
on protein synthesis and amino acid transporter expression.
Together, these factors suggest that DHT may be a better
therapeutic target for the management of sarcopenia than T.
Summary
The results reported in this study show that at all ages inves-
tigated, protein synthesis was always higher in slow-twitch
(type 1) ﬁbres than in fast-twitch (type 2) ﬁbres and that it
decreased with ageing in both ﬁbre types. Furthermore, the
decline of protein synthesis with age was always greater in
the fast-twitch ﬁbres than in the slow-twitch ﬁbres and was
accompanied by a corresponding reduction in the levels of
SNAT2 and LAT2 proteins but not their mRNA. The ﬁndings
also show that treating the muscle ﬁbre bundles with physio-
logical concentrations of DHT abolished the effects of ageing
on both protein synthesis and amino acid transporter expres-
sion, suggesting that sarcopenia may arise from an age-
dependent decline in protein synthesis caused, in part, by
lack of or the low bioavailability of DHT. From these ﬁndings,
we postulate that DHT treatment may have clinical implica-
tions in the management of sarcopenia.
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